DIDB has been updated with the following new features:
- AUC and Cmax GMRs (90% CI) are now systematically presented in the study results view (when available) and are used to calculate changes in exposure data
- Links to PGx external resources have been added to pharmacogenetics queries to provide users with additional contextual information
- New drug characteristic “PGx (FDA label)” highlights drugs with PGx-related recommendations in FDA label
- Continuous expansion of compound PK parameters
Feel free to contact us if you experience any issues or if you have any questions or suggestions. Your feedback is always greatly valued!